What is Royalty Pharma's total equity?

Royalty Pharma (RPRX) reported total equity of $9.94B in Q1 2026.

How has Royalty Pharma's total equity changed year-over-year?

Royalty Pharma's total equity increased by 1.6% year-over-year, from $9.78B to $9.94B.

What is the long-term trend for Royalty Pharma's total equity?

Over 5 years (2020 to 2025), Royalty Pharma's total equity has grown at a -0.4% compound annual growth rate (CAGR), from $9.9B to $9.71B.

What does total equity mean?

Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Royalty Pharma RPRX Total Equity

Total Equity at other companies

XOMA CorporationXOMA

$92.88M+9.7%

Ligand PharmaceuticalsLGND

$997.32M+25.4%

BridgeBio PharmaBBIO

-$2.28B-38.2%

Rigel PharmaceuticalsRIGL

$399.9M+2,054%

Roivant SciencesROIV

$4.53B-3.4%

Ionis PharmaceuticalsIONS

$491.41M+3.3%

Other financials

Income statement

See full

Revenue$630.6M+11.0%

Operating income$563.0M+5.4%

Net income$294.7M+23.1%

EPS (diluted)$0.67+21.8%

Balance sheet

See full

Cash & equivalents$586.4M-46.1%

Total debt$9.0B+17.8%

Total assets$19.8B+12.5%

Cash flow

See full

Operating cash flow$718.2M+20.5%

Valuation

See full

Market cap$24.85B+72.3%

Enterprise value$33.24B+52.8%

P/E30×+15.9×

P/S10.2×+3.9×

Profitability

See full

Operating margin65.1%-18.9pp

Net margin33.9%-14.4pp

Returns & leverage

See full

Return on equity8.4%-2.7pp

Debt / equity0.9×+0.1×

Current ratio2.7×+1.1×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest.

The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Royalty Pharma's total equity?: Royalty Pharma (RPRX) reported total equity of $9.94B in Q1 2026.
How has Royalty Pharma's total equity changed year-over-year?: Royalty Pharma's total equity increased by 1.6% year-over-year, from $9.78B to $9.94B.
What is the long-term trend for Royalty Pharma's total equity?: Over 5 years (2020 to 2025), Royalty Pharma's total equity has grown at a -0.4% compound annual growth rate (CAGR), from $9.9B to $9.71B.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.